Product Description Model NO.: USP Certification: GMP, SGS Type: Analysis reagent Volatile: Not Volatile Trademark: REACHEVER Specification: GMP Function: Cardiovascular Agents Grade Standard: Medicine Grade State: Crystalline Powder Assay: 99.75% Transport Package: 25kg/Drum Origin: China(Mainland)
TREATMENT OF MENIERE'S SYNDROME BETAHISTINE DIHYDROCHLORIDE

Cas No.:5579-84-0
EINECS No.:226-966-5
Standard:USP30  
Assay:99.0~101.0%

MF :C8H14Cl2N2
Place of Origin:China (Mainland)
Packaging Details:25kg drum


USE:
Used in the treatment of meniere's syndrome, cerebral arteriosclerosis, brain, and high blood pressure caused by dizziness, vomiting, and tinnitus.
COA:

ITEMS	SPECIFICATION	RESULTS
Appearance	White to almost crystalline powder, very hygroscopic	Conforms
Assay	99.0%-101.0%	99.75%
Ph	2~3	2.5
Loss on drying	Not more than 1.0%	0.3%
Sulphated ash	Not more than 0.1%	0.06%
Identification	IR: Similar to the reference standard HPLC: Similar to the reference standard	Conforms
Residual solvents (2-propanol)	Not more than 0.5%	0.20%
Solubility	Very soluble in water Freely soluble in alcohol (96%) Practically insoluble in 2-propanol	Conforms
Clarity of solution	(0.1g in 10ml carbon dioxide free water)-clear	Conforms
2-(2-Hydroxyethyl)pyridine	Not more than 0.2%	Not detected
2-Vinylpyridine	Not more than 0.2%	0.06%
N-Methyl-N,N-bis(2-Pyridin-2-Yl-ethyl) amine	Not more than 0.2%	0.13%
Other individual impurity	Not more than 0.1%	Conforms
Total impurities	Not more than 0.5%	0.3%
Conclusion: It conforms to the USP30 STANDARD.

Contact us if you need more details on Betahistine Dihydrochloride. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Treatment of Menieres Syndrome、Treatment of Cerebral Arteriosclerosis. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Pharmaceutical Ingredient > API For Cardiovascular & Blood System Drug